BidaskClub Upgrades NantHealth (NH) to Sell

NantHealth (NASDAQ:NH) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Tuesday.

Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of NantHealth from a “buy” rating to a “hold” rating in a research report on Tuesday. Canaccord Genuity dropped their target price on shares of NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, November 17th. Finally, Jefferies Group reissued a “buy” rating and set a $5.00 target price on shares of NantHealth in a research report on Thursday, September 28th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $8.05.

NantHealth (NH) traded up $0.01 during trading on Tuesday, hitting $3.77. 194,612 shares of the company’s stock traded hands, compared to its average volume of 157,598. NantHealth has a 1 year low of $2.60 and a 1 year high of $10.19. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.36 and a current ratio of 2.38. The company has a market cap of $407.32, a PE ratio of -2.12 and a beta of -1.50.

NantHealth (NASDAQ:NH) last posted its earnings results on Thursday, November 9th. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. NantHealth had a negative net margin of 225.76% and a negative return on equity of 46.09%. The firm had revenue of $21.76 million for the quarter, compared to analysts’ expectations of $29.42 million. During the same quarter last year, the firm earned ($0.18) EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. sell-side analysts expect that NantHealth will post -1.35 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP raised its holdings in shares of NantHealth by 154.7% in the 3rd quarter. GSA Capital Partners LLP now owns 72,600 shares of the company’s stock worth $299,000 after purchasing an additional 44,100 shares during the period. Highbridge Capital Management LLC raised its holdings in shares of NantHealth by 6.5% in the 3rd quarter. Highbridge Capital Management LLC now owns 250,000 shares of the company’s stock worth $1,030,000 after purchasing an additional 15,264 shares during the period. National Planning Corp raised its holdings in shares of NantHealth by 21.1% in the 3rd quarter. National Planning Corp now owns 138,700 shares of the company’s stock worth $656,000 after purchasing an additional 24,200 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of NantHealth in the 3rd quarter worth approximately $365,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of NantHealth in the 3rd quarter worth approximately $180,000. 7.10% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/bidaskclub-upgrades-nanthealth-nh-to-sell.html.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply